Nothing Special   »   [go: up one dir, main page]

Barnes et al., 1975 - Google Patents

Cyproterone acetate: a study involving two volunteers with idiopathic hirsutism

Barnes et al., 1975

Document ID
11877272066642174523
Author
Barnes E
Irvine W
Hunter W
Ismail A
Publication year
Publication venue
Clinical Endocrinology

External Links

Snippet

Two female volunteers, of menstrual age, with severe idiopathic hirsutism were treated for eight cycles and fifteen cycles respectively with cyproterone acetate 50 mg twice daily on days 5‐14 of the cycle. In all but one cycle, ethinyl oestradiol in a dose of 50 μg daily from …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00—Drug, bio-affecting and body treating compositions
    • Y10S514/899—Menstrual disorder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00—Cosmetic or similar toilet preparations
    • A61K8/18—Cosmetic or similar toilet preparations characterised by the composition
    • A61K8/30—Cosmetic or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21

Similar Documents

Publication Publication Date Title
Neumann Pharmacology and potential use of cyproterone acetate
ANDREYKO et al. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin)
DE19619045C1 (en) Use of combination products for the treatment of hypogonadal men and men with pituitary disorders
EP0310541B1 (en) Antigestagenic and antioestrogenic compounds for the introduction of labour and interruption of pregnancy, as well as for the treatment of gynecologic disorders
Girard et al. Cyproteroneacetate and ACTH adrenal function
ISMAIL et al. The evaluation of the role of androgens in hirsutism and the use of a new anti-androgen “cyproterone acetate” for therapy
CZ278094A3 (en) Competitive progesteron antagonist and use thereo competitive progesteron antagonist and use thereof f
JP2002541126A (en) Low-dose estrogen intermittent hormone replacement therapy
Brown et al. The effect of norethisterone and its acetate on ovarian and pituitary function during the menstrual cycle
LU83545A1 (en) USE OF THE COMBINATION OF AN AROMATASE INHIBITOR WITH AN ANTIANDROGEN FOR PROPHYLAXIS AND THERAPY OF PROSTATE HYPERPLASIA
DE60223795T2 (en) Tetrahydroxylated estrogen-containing drug delivery system for use in hormonal contraception
Kim et al. Plasma levels of estrogens, androgens and progesterone during normal and dexamethasone-treated cycles
Christy et al. On the rate of hydrocortisone clearance from plasma in pregnant women and in patients with Laennec's cirrhosis
Barnes et al. Cyproterone acetate: a study involving two volunteers with idiopathic hirsutism
CASEY Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth
Drill Endocrine properties and long-term safety of oral contraceptives
Geist et al. The use of testosterone propionate in functional bleeding
EP0310542B1 (en) Antigestagenic and antioestrogenic compounds for the treatment of hormone-dependent tumours
Greenblatt et al. Delay of menstruation with norethindrone, an orally given progestational compound
CORREA de OLIVEIRA et al. A new treatment for hirsutism
Hancock et al. The use of oestrogen/progestogen preparations in the treatment of hirsutism in the female
Fotherby Pharmacology of natural and synthetic estrogens
Pochi Acne in premature ovarian failure: reestablishment of cyclic flare-ups with medroxyprogesterone acetate therapy
Ismail et al. Hirsutism: a disorder frequently associated with menstrual abnormalities
Neumann Pharmacology and clinical use of antiandrogens: a short review